Abstract: A method for measuring drop time of a control rod cluster integrated with a rod position measurement device is provided, wherein the method is used to measure the drop time of each control rod cluster, and includes: Si, monitoring a voltage Ua of coils in Group A to capture a rod cluster drop signal; S2, searching a point (tmax, Vmax) with a maximum drop speed or with a local maximum drop speed; S3, retroactively calculating, from tmax, an end of a time period T4 when the control rod cluster starts to drop; S4, retroactively searching, from a minimum value point of a drop reference signal DROPref, a start of the time period T4 when the drop reference signal DROPref drops from a maximum value to 33% thereof; and S5, determining, from tmax forward, a time point t6 when a drop speed of the control rod cluster is lower than 0.

Abstract: The present disclosure provides a novel compound for effectively inhibiting the activity of CD73, a preparation method thereof, and use thereof in the preparation of drugs, and the novel compound is a compound represented by formula I, or a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt, or prodrug thereof.

Abstract: The present disclosure provides a novel compound effective in antagonizing EP4, which is a compound represented by Formula I, or a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug of the compound represented by Formula I: wherein: R1 is selected from —CH3, —CHF2, and —CF3; R2 is selected from C2-C6 alkyl, C3-C6 cycloalkyl, C2-C6 halogen-substituted alkyl, C3-C6 halogen-substituted cycloalkyl; R3 is selected from hydrogen, halogen, C1-C2 alkyl, C1-C2 fluorine- or chlorine-substituted alkyl; R4 is selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxyl, C1-C6 halogen-substituted alkyl, C1-C6 halogen-substituted alkoxyl.

Abstract: A compound of formula (I) or (II) and use of the compound in the preparation of drugs for treating cancer are disclosed. The study shows that the compounds can inhibit the growth of many kinds of tumor cells, can be used for targeting epidermal growth factor receptor (EGFR), and particularly can inhibit tumor cells with single or multiple mutations of EGFR (T790M). Therefore, the compound can be used as EGFR inhibitor to treat cancer and has a relatively large application value.